These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18548321)

  • 1. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
    Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
    Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
    Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
    Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
    Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
    Labidi SI; Bachelot T; Ray-Coquard I; Mosbah K; Treilleux I; Fayette J; Favier B; Galy G; Blay JY; Guastalla JP
    Clin Breast Cancer; 2009 May; 9(2):118-21. PubMed ID: 19433393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
    Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response].
    Yoshida T; Horiguchi J; Koibuchi Y; Kanoh T; Iijima K; Yoshida M; Kikuchi M; Takata D; Oyama T; Iino Y; Morishita Y
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):907-10. PubMed ID: 15222110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
    Suzuki M; Kimijima I; Ishii M
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1519-23. PubMed ID: 19755824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
    Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
    Ikeda M; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2917-20. PubMed ID: 21160270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
    Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A long survival of a patient with poor performance status who suffered from advanced right breast cancer with multiple lung metastases controlled by trastuzumab as a key drug].
    Fujikawa T; Mukai K; Tanaka A; Abe T; Yoshimoto Y; Tada S; Maekawa H; Shimoike N; Tanaka H; Kawashima T; Yokota T
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):1009-12. PubMed ID: 22705704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Two cases treated with trastuzumab as primary chemotherapy].
    Murakami K; Sakata H; Miyazawa Y; Matsushita K; Akutsu Y; Nishimori T; Yoneyama Y; Usui A; Kano M; Matsubara H; Ochiai T
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1683-7. PubMed ID: 17940391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
    Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
    Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
    Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
    J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.